Dr Reddys Laboratories (RDY) Capital Expenditures (2009)
Dr Reddys Laboratories (RDY) posted quarterly Capital Expenditures of -$12.0 million for Q4 2009, up 42.86% on a QoQ basis from -$21.0 million in Q3 2009.
Dr Reddys Laboratories (RDY) Capital Expenditures (2009) Analysis & Trends
Dr Reddys Laboratories (RDY) has reported Capital Expenditures for 1 consecutive years, with -$12.0 million the latest figure, recorded in Q4 2009.
- Quarterly Capital Expenditures changed N/A year-over-year to -$12.0 million in Q4 2009, while the trailing twelve-month figure through Dec 2009 was -$70.5 million (changed N/A YoY) and the FY2026 annual result came in at $249.0 million, down 22.67% from the prior year.
- Capital Expenditures rose to -$12.0 million in Q4 2009 per RDY's latest filing, from -$21.0 million in the prior quarter.
- Over the last five years, Capital Expenditures for RDY reached as high as -$12.0 million in Q4 2009 and fell as low as -$21.0 million in Q3 2009.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Dr Reddys Laboratories | 9.82 Bn | 9.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2009 | -12.00 Mn |
| Dec 31, 2009 | -12.00 Mn |
| Sep 30, 2009 | -21.00 Mn |
| Sep 30, 2009 | -21.00 Mn |
| Jun 30, 2009 | -15.00 Mn |
| Jun 30, 2009 | -15.00 Mn |